We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Genuit Group Plc | LSE:GEN | London | Ordinary Share | GB00BKRC5K31 | ORD GBP0.001 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-7.50 | -1.69% | 436.50 | 436.00 | 437.00 | 452.50 | 433.50 | 452.50 | 201,248 | 16:29:55 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Plastics Pipe | 586.5M | 38.5M | 0.1551 | 28.14 | 1.08B |
TIDMGEN
Media Release
COPENHAGEN, Denmark; September 6, 2022
https://www.globenewswire.com/Tracker?data=Wynhv1AyHdFrUknEAyjNxs0WdwE-nVM8yZ4OxfQYinlU9CxPYnGdVvtzntXSZR1LYisD9URwiTyMzup_t50Sug== Genmab A/S (Nasdaq: GMAB) announced today that its Chief Executive Officer Jan van de Winkel, Ph.D. and Chief Financial Officer Anthony Pagano will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference at 8:00 AM EDT / 2:00 PM CEST on September 13, 2022. A webcast of the event, which will include brief opening remarks followed by a question-and-answer session, will be available on Genmab's website at https://ir.genmab.com/events-and-presentations#content
About Genmab
Genmab is an international biotechnology company with a core purpose to improve the lives of people with cancer. For more than 20 years, Genmab's vision to transform cancer treatment has driven its passionate, innovative and collaborative teams to invent next-generation antibody technology platforms and leverage translational research and data sciences, fueling multiple differentiated cancer treatments that make an impact on people's lives. To develop and deliver novel therapies to patients, Genmab has formed 20+ strategic partnerships with biotechnology and pharmaceutical companies. Genmab's proprietary pipeline includes bispecific T-cell engagers, next-generation immune checkpoint modulators, effector function enhanced antibodies and antibody-drug conjugates.
Genmab is headquartered in Copenhagen, Denmark with locations in Utrecht, the Netherlands, Princeton, New Jersey, U.S. and Tokyo, Japan. For more information, please visit Genmab.com https://www.globenewswire.com/Tracker?data=Wynhv1AyHdFrUknEAyjNxgndkkeSCSuSdbBahcjzSHtPbyID0ROnT_8Wcmr_mzRmaOBqVV0yL0_Q8O1yZypc0A== and follow us on Twitter.com/Genmab https://www.globenewswire.com/Tracker?data=ncOgil3zQ7JEmFMO6-AwTHJoTEnn8t8ESuxS2Ecul1FLfDnke-4vawpvymollSsOD1ul7qIWwWSOxFXuiOeUlh5Uyi5hDVthl28aVG6MTj8= .
Contact:
Marisol Peron, Senior Vice President, Communications and Corporate Affairs
T: +1 609 524 0065; E: mmp@genmab.com https://www.globenewswire.com/Tracker?data=RAt_rEy6g59WQmoiyvVHR_03amETGzov_BqCXDbDnk1ZoEeNolP952zS1hMZHTB7bSeUvzZoVeDd_9GaIpCWxg==
Andrew Carlsen, Vice President, Head of Investor Relations
T: +45 3377 9558; E: acn@genmab.com https://www.globenewswire.com/Tracker?data=mutSpuvecDB9RI5IZ9rvd1j2_rxCS_WnlSA43P23X-cOK28qq86v03aZr9jA6ZMfJ5UCpMJ9f-lhe6suZFo6Lw==
This Media Release contains forward looking statements. The words "believe", "expect", "anticipate", "intend" and "plan" and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab's most recent financial reports, which are available on https://www.globenewswire.com/Tracker?data=1N2bafVqI7qvYRKWJN-YrbZpKmMjWLaBRx8AisgFh9Erhcgjt7djKTzg77gSDpiDCi40EqiOFwfCRmIjhiJa3Q== www.genmab.com and the risk factors included in Genmab's most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at https://www.globenewswire.com/Tracker?data=1N2bafVqI7qvYRKWJN-YrVDkHF8skHR9du3UZcXu_DUwF4tNJcLkNHFVczYkFqyQQ1w-cdp7yqV7xGn_5P8RiTsbSRwICPUomZhPVYV7Ee8= www.sec.gov. Genmab does not undertake any obligation to update or revise forward looking statements in this Media Release nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.
Genmab A/S and/or its subsidiaries own the following trademarks: Genmab(R) ; the Y-shaped Genmab logo(R) ; Genmab in combination with the Y-shaped Genmab logo(R) ; HuMax(R) ; DuoBody(R) ; DuoBody in combination with the DuoBody logo(R) ; HexaBody(R) ; HexaBody in combination with the HexaBody logo(R) ; DuoHexaBody(R) and HexElect(R) .
Media Release no. i13
CVR no. 2102 3884
LEI Code 529900MTJPDPE4MHJ122
Genmab A/S
Kalvebod Brygge 43
1560 Copenhagen V
Denmark
Attachment
-- 220906_MRi13_Morgan Stanley https://ml-eu.globenewswire.com/Resource/Download/932c23c0-53a3-4713-8c63-45832c1977a6
(END) Dow Jones Newswires
September 06, 2022 10:53 ET (14:53 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Genuit Chart |
1 Month Genuit Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions